Jpmorgan Chase & CO Gossamer Bio, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GOSS
# of Institutions
104Shares Held
175MCall Options Held
453KPut Options Held
543K-
Nea Management Company, LLC Timonium, MD18.1MShares$16.1 Million1.54% of portfolio
-
Artal Group S.A. Luxembourg, N413.3MShares$11.8 Million0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$10.5 Million0.0% of portfolio
-
Octagon Capital Advisors LP New York, NY9.19MShares$8.18 Million1.91% of portfolio
-
Arch Venture Management, LLC Chicago, IL8.06MShares$7.17 Million4.25% of portfolio
About Gossamer Bio, Inc.
- Ticker GOSS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,954,000
- Market Cap $83.6M
- Description
- Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...